Picture of Zydus Lifesciences logo

ZYDUSLIFE — Zydus Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

India's Zydus Life gains on deal to launch hypertension drug in US

BUZZ-India's Zydus Life gains on deal to launch hypertension drug in US

** Drug maker Zydus Lifesciences ZYDU.NS shares rise as much as 2.27% to 1,164.80 rupees apiece

** Rise after ZYDU announces partnership with MSN Laboratories and launches Riociguat tablets in the US

** ZYDU and MSN are the first companies to launch generic Riociguat, a drug indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension

** According to drugmaker Bayer's annual report 2025, global sales of Adempas (the brand name of riociguat) were approximately $850 million in 2025

** ZYDU shares are up about 27% in 2026 so far, outperforming the 16.4% rise in the pharma index .NIPHARM, according to exchange data


(Reporting by Bharath Rajeswaran in Bengaluru)

((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))

Recent news on Zydus Lifesciences

See all news